biotechnology - Publications - Faculty & Research - Harvard Business School

Filter Results: (620)

Filter Results: (620)

Show Results For

← Page 8 of 620 Results →

January 2020
Case

Celata Bioinnovations

By: John R. Wells and Benjamin Weinstock

In December 2019, Jon Hu (HBS ‘19) and Dr. Samantha Dale Strasser, co-founders of Celata Bioinnovations, were raising $1 million to launch their company. They had founded Celata less than six months earlier with the aim of redefining the drug discovery process.... View Details

December 2006 (Revised October 2007)
Case

Monsanto: Realizing Biotech Value in Brazil

By: David E. Bell and Mary L. Shelman

In 2003, Monsanto's patented "Roundup Ready" technology was used illegally on 70-80% of the soybean area in southern Brazil. Under pressure from U.S. soybean growers, who were paying to license the technology, the firm implemented an innovative delivery-based... View Details

Keywords: Plant-Based Agribusiness; Patents; Lawfulness; Emerging Markets; Product Development; Biotechnology Industry; Biotechnology Industry; Brazil

September 2023 (Revised December 2023)
Case

TetraScience: Noise and Signal

By: Thomas R. Eisenmann and Tom Quinn

In 2019, TetraScience CEO “Spin” Wang needed advice. Five years earlier, he had cofounded a startup that saw early success with a hardware product designed to help laboratory scientists in the biotechnology and pharmaceutical spaces more easily collect data from... View Details

Keywords: Entrepreneurship; Business Growth and Maturation; Business Organization; Restructuring; Forecasting and Prediction; Digital Platforms; Analytics and Data Science; AI and Machine Learning; Organizational Structure; Network Effects; Competitive Strategy; Biotechnology Industry; Biotechnology Industry; United States; Boston

Research Summary

Overview

The research activity of Stefano Denicolai regards the management of innovation and technology. His recent works investigate if and how the investment in intangible assets (IA) - especially knowledge assets, such as patents or copyright - impacts on the firm... View Details

Research Summary

3. Emergence and Early Growth of a New Venture in an Unfriendly Environment: The Role of a Business Group

Abstract: How can an established organization ease the emergence and early growth of a new venture in an unfriendly environment? To answer this question, I describe and analyze the foundation and early life of two biotechnology start-ups at the... View Details

February 2021
Case

Digital Manufacturing at Amgen

By: Shane Greenstein, Kyle R. Myers and Sarah Mehta

This case discusses efforts made by biotechnology (biotech) company Amgen to introduce digital technologies into its manufacturing processes. Doing so is complicated by the fact that the process for manufacturing biologics—or therapeutics made from living cells—is... View Details

2015
Working Paper

Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules

By: Pierre Azoulay, Joshua S. Graff Zivin, Danielle Li and Bhaven N. Sampat

We quantify the impact of scientific grant funding at the National Institutes of Health (NIH) on patenting by pharmaceutical and biotechnology firms. Our paper makes two contributions. First, we use newly constructed bibliometric data to develop a method for flexibly... View Details

Keywords: Economics Of Science; Patenting; Academic Reserach; NIH; Knowledge Spillovers; Patents; Research; Government and Politics

May 2006 (Revised June 2006)
Case

Codon Devices

By: Joseph B. Lassiter III and David Kiron

In December 2005, 40-year-old John Danner was about to make his first presentation to the board of directors of Codon Devices, a one-year-old biotechnology start-up based in Cambridge, Massachusetts. After a month as the company's CEO, Danner was prepared to lay out... View Details

Keywords: Strategic Planning; Venture Capital; Intellectual Property; Governing and Advisory Boards; Genetics; Competitive Advantage; Science-Based Business; Business Startups; Growth and Development Strategy; Biotechnology Industry; Cambridge

Find at Harvard

March 1996
Case

Erox Corporation: Leverage Marketing

Erox Corp. is a biotechnology start-up that creates products containing synthetic human pheromones. It was founded in 1989, went public in 1993, and brought in a turnaround team in 1994. Sales ramped from $110,000 in 1993 to over $1 million in 1994, with prospects for... View Details

Keywords: Marketing Communications; Entrepreneurship; Biotechnology Industry

February 2003
Article

Which Ties Matter When? The Contingent Effects of Interorganizational Partnerships on IPO Success

By: Ranjay Gulati and M. Higgins

This paper investigates the contingent value of interorganizational relationships at the time of a young firm's initial public offering (IPO). We compare the signaling value to young firms of having ties with two types of interorganizational partnerships: endorsement... View Details

Keywords: Interorganizatonal Relationships; Networks; Venture Capital; Initial Public Offering; Entrepreneurship; Biotechnology Industry

Find at Harvard

March 1992
Case

Amgen, Inc.: Planning the Unplannable

By: Nitin Nohria

By the early 1990s, Amgen--a pharmaceutical company started little over a decade ago as Applied Molecular Genetics--was within range of becoming a billion-dollar company. With two extremely successful biotechnology drugs on the market, Amgen stood as the largest and... View Details

Keywords: Growth and Development Strategy; Strategic Planning; Success; Risk and Uncertainty; Pharmaceutical Industry

April 2009
Case

GSK's Acquisition of Sirtris: Independence or Integration?

By: Toby E. Stuart and James Weber

An executive from pharmaceutical company GSK must choose how much to integrate a recently acquired biotechnology firm, Sirtris. Moncef Slaoui, GSK's global head of R&D, championed the acquisition of Sirtris to gain access to its potentially revolutionary science.... View Details

Keywords: Mergers and Acquisitions; Resource Allocation; Organizational Change and Adaptation; Organizational Culture; Organizational Structure; Research and Development; Science-Based Business; Integration

April 2002
Case

In vivo to in vitro to in silico: Coping with Tidal Waves of Data at Biogen

By: Juan Enriquez-Cabot, Gary P. Pisano and Gaye Bok

Biogen is a successful biotech company facing a critical juncture. CEO John Mullen ponders how technological changes introduced into the research function will shape larger corporate decisions. This world in which biotechnology companies operated had changed... View Details

Keywords: Change; Decisions; Product Development; Research and Development; Expansion; Technology; Biotechnology Industry

July–August 2021
Article

Lowering the Bar? External Conditions, Opportunity Costs, and High-Tech Startup Outcomes

By: Annamaria Conti and Maria P. Roche

We assess the heterogeneous impact of economic downturns on individuals’ decisions to bring high-technology ideas to the market in the form of new ventures. We thereby examine how worsening labor market conditions influence individuals’ opportunity costs of starting... View Details

Keywords: Necessity Entrepreneurship; Economic Conditions; Recessions; High-tech Startups; Opportunity Costs; Entrepreneurship; Economic Slowdown and Stagnation; Business Startups; Information Technology; Performance; Labor

Find at Harvard

15 Sep 2010
Working Paper Summaries

From Bench to Board: Gender Differences in University Scientists’ Participation in Commercial Science

Keywords: by Waverly W. Ding, Fiona Murray & Toby E. Stuart; Biotechnology

October 2012
Case

GSK's Acquisition of Sirtris: Independence or Integration? (Abridged)

By: Toby Stuart and James Weber

An executive from pharmaceutical company GSK must choose how much to integrate a recently acquired biotechnology firm, Sirtris. Moncef Slaoui, GSK's global head of R&D, championed the acquisition of Sirtris to gain access to its potentially revolutionary science.... View Details

Keywords: Mergers and Acquisitions; Resource Allocation; Organizational Change and Adaptation; Organizational Culture; Organizational Structure; Research and Development; Science-Based Business; Integration

2008
Chapter

The Evidence Does Not Speak for Itself: Expert Witnesses and the Organization of DNA-Typing Companies

By: Arthur A. Daemmrich

During the past 15 years, new biotechnology companies have promoted DNA typing as a sophisticated criminal and paternity identification technique. Private testing laboratories produce results that link individuals with crime scenes and fathers to their children.... View Details

Keywords: Governing Rules, Regulations, and Reforms; Courts and Trials; Organizational Structure; Practice; Genetics; Science-Based Business; Trust; Commercialization; Vertical Integration

Web

Curriculum | MBA

likely in the life sciences or biotech space. Capstone Overview First Year AUGUST Harvard Business School Online CORe Harvard Business School NextGen Biotechnology Harvard Department of Stem Cell and Regenerative Biology FALL TERM Data... View Details

January 2011 (Revised July 2012)
Case

Arcadia Biosciences: Seeds of Change (Abridged)

By: Arthur A. Daemmrich

Arcadia Biosciences is seeking to introduce genetically modified rice to China that will lower farmers' costs and generate environmental benefits through reduced greenhouse gas emissions. The case describes challenges facing this small agricultural biotechnology... View Details

Keywords: Plant-Based Agribusiness; Intellectual Property; Genetics; Environmental Sustainability; Science-Based Business; Climate Change; Biotechnology Industry; Biotechnology Industry; China

Person Page

Press / Media

By: Gary P. Pisano

Thought Leader: Gary Pisano

by Amy Bernstein, strategy+business, Summer 2007

A leading student of the biotech business describes the problems holding the industry back, and how it can overcome... View Details

←
8
9
…
30
31
→